nodes	percent_of_prediction	percent_of_DWPC	metapath
Perhexiline—CYP2B6—Sorafenib—thyroid cancer	0.171	0.295	CbGbCtD
Perhexiline—CYP2B6—Doxorubicin—thyroid cancer	0.104	0.179	CbGbCtD
Perhexiline—CYP3A4—Vandetanib—thyroid cancer	0.0873	0.151	CbGbCtD
Perhexiline—CYP2D6—Sorafenib—thyroid cancer	0.0828	0.143	CbGbCtD
Perhexiline—CYP3A4—Sorafenib—thyroid cancer	0.0526	0.0907	CbGbCtD
Perhexiline—CYP2D6—Doxorubicin—thyroid cancer	0.0502	0.0866	CbGbCtD
Perhexiline—CYP3A4—Doxorubicin—thyroid cancer	0.0319	0.055	CbGbCtD
Perhexiline—Urogenital disorder—Sorafenib—thyroid cancer	0.0287	0.143	CcSEcCtD
Perhexiline—CPT2—Import of palmitoyl-CoA into the mitochondrial matrix—RXRA—thyroid cancer	0.019	0.0954	CbGpPWpGaD
Perhexiline—CPT1A—Import of palmitoyl-CoA into the mitochondrial matrix—RXRA—thyroid cancer	0.0132	0.0662	CbGpPWpGaD
Perhexiline—Balance disorder—Vandetanib—thyroid cancer	0.0128	0.0636	CcSEcCtD
Perhexiline—CPT1A—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.0123	0.0615	CbGpPWpGaD
Perhexiline—CPT2—PPAR Alpha Pathway—CDK1—thyroid cancer	0.0118	0.0591	CbGpPWpGaD
Perhexiline—CPT2—PPAR Alpha Pathway—RXRA—thyroid cancer	0.0109	0.0548	CbGpPWpGaD
Perhexiline—Torsade de pointes—Vandetanib—thyroid cancer	0.00996	0.0496	CcSEcCtD
Perhexiline—CPT1A—PPAR Alpha Pathway—CDK1—thyroid cancer	0.00815	0.0409	CbGpPWpGaD
Perhexiline—CPT1A—RORA activates circadian gene expression—RXRA—thyroid cancer	0.00781	0.0392	CbGpPWpGaD
Perhexiline—CPT1A—PPAR Alpha Pathway—RXRA—thyroid cancer	0.00757	0.038	CbGpPWpGaD
Perhexiline—Cachexia—Epirubicin—thyroid cancer	0.00609	0.0304	CcSEcCtD
Perhexiline—Cachexia—Doxorubicin—thyroid cancer	0.00564	0.0281	CcSEcCtD
Perhexiline—Polyneuropathy—Epirubicin—thyroid cancer	0.00534	0.0266	CcSEcCtD
Perhexiline—Hypoglycaemia—Vandetanib—thyroid cancer	0.0052	0.0259	CcSEcCtD
Perhexiline—Polyneuropathy—Doxorubicin—thyroid cancer	0.00494	0.0246	CcSEcCtD
Perhexiline—CPT2—PPAR Alpha Pathway—CCND1—thyroid cancer	0.0049	0.0246	CbGpPWpGaD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—RET—thyroid cancer	0.00457	0.0229	CbGpPWpGaD
Perhexiline—CPT2—saliva-secreting gland—thyroid cancer	0.00453	0.228	CbGeAlD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00425	0.0213	CbGpPWpGaD
Perhexiline—CPT1A—Circadian Clock—RXRA—thyroid cancer	0.00416	0.0209	CbGpPWpGaD
Perhexiline—Weight decreased—Vandetanib—thyroid cancer	0.00396	0.0197	CcSEcCtD
Perhexiline—CYP2B6—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00385	0.0193	CbGpPWpGaD
Perhexiline—CPT1A—Circadian rythm related genes—NKX2-1—thyroid cancer	0.00364	0.0183	CbGpPWpGaD
Perhexiline—CPT2—PPARA activates gene expression—RXRA—thyroid cancer	0.00344	0.0173	CbGpPWpGaD
Perhexiline—CPT1A—PPAR Alpha Pathway—CCND1—thyroid cancer	0.0034	0.0171	CbGpPWpGaD
Perhexiline—CPT2—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.00337	0.0169	CbGpPWpGaD
Perhexiline—CPT1A—Circadian Clock—HIF1A—thyroid cancer	0.00309	0.0155	CbGpPWpGaD
Perhexiline—CPT1A—thyroid gland—thyroid cancer	0.00292	0.147	CbGeAlD
Perhexiline—Tremor—Vandetanib—thyroid cancer	0.00286	0.0143	CcSEcCtD
Perhexiline—Optic neuritis—Epirubicin—thyroid cancer	0.00283	0.0141	CcSEcCtD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.00282	0.0142	CbGpPWpGaD
Perhexiline—CPT2—thyroid gland—thyroid cancer	0.00277	0.139	CbGeAlD
Perhexiline—Loss of consciousness—Vandetanib—thyroid cancer	0.00268	0.0134	CcSEcCtD
Perhexiline—Weight decreased—Sorafenib—thyroid cancer	0.00267	0.0133	CcSEcCtD
Perhexiline—Convulsion—Vandetanib—thyroid cancer	0.00265	0.0132	CcSEcCtD
Perhexiline—Optic neuritis—Doxorubicin—thyroid cancer	0.00262	0.013	CcSEcCtD
Perhexiline—CPT1A—head—thyroid cancer	0.00259	0.13	CbGeAlD
Perhexiline—Neuropathy peripheral—Sorafenib—thyroid cancer	0.00258	0.0129	CcSEcCtD
Perhexiline—CPT2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00256	0.0129	CbGpPWpGaD
Perhexiline—CPT2—head—thyroid cancer	0.00245	0.123	CbGeAlD
Perhexiline—CPT1A—PPARA activates gene expression—RXRA—thyroid cancer	0.00239	0.012	CbGpPWpGaD
Perhexiline—CPT1A—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.00234	0.0117	CbGpPWpGaD
Perhexiline—CPT2—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.00232	0.0117	CbGpPWpGaD
Perhexiline—Insomnia—Vandetanib—thyroid cancer	0.00225	0.0112	CcSEcCtD
Perhexiline—Paraesthesia—Vandetanib—thyroid cancer	0.00224	0.0111	CcSEcCtD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—SST—thyroid cancer	0.00223	0.0112	CbGpPWpGaD
Perhexiline—Flushing—Sorafenib—thyroid cancer	0.0022	0.0109	CcSEcCtD
Perhexiline—CPT2—PPARA activates gene expression—PPARG—thyroid cancer	0.00217	0.0109	CbGpPWpGaD
Perhexiline—Decreased appetite—Vandetanib—thyroid cancer	0.00217	0.0108	CcSEcCtD
Perhexiline—Fatigue—Vandetanib—thyroid cancer	0.00215	0.0107	CcSEcCtD
Perhexiline—CPT2—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.00213	0.0107	CbGpPWpGaD
Perhexiline—Liver injury—Epirubicin—thyroid cancer	0.00207	0.0103	CcSEcCtD
Perhexiline—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00204	0.0102	CcSEcCtD
Perhexiline—Abdominal pain—Vandetanib—thyroid cancer	0.00197	0.00981	CcSEcCtD
Perhexiline—Liver injury—Doxorubicin—thyroid cancer	0.00191	0.00954	CcSEcCtD
Perhexiline—Syncope—Sorafenib—thyroid cancer	0.00185	0.0092	CcSEcCtD
Perhexiline—CPT1A—lymph node—thyroid cancer	0.00181	0.091	CbGeAlD
Perhexiline—Loss of consciousness—Sorafenib—thyroid cancer	0.00181	0.00902	CcSEcCtD
Perhexiline—Asthenia—Vandetanib—thyroid cancer	0.00179	0.00891	CcSEcCtD
Perhexiline—Gait disturbance—Epirubicin—thyroid cancer	0.00178	0.00889	CcSEcCtD
Perhexiline—CPT1A—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00177	0.00891	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—MINPP1—thyroid cancer	0.00177	0.00888	CbGpPWpGaD
Perhexiline—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00175	0.00877	CbGpPWpGaD
Perhexiline—Hepatocellular injury—Epirubicin—thyroid cancer	0.00174	0.00867	CcSEcCtD
Perhexiline—CPT2—lymph node—thyroid cancer	0.00172	0.0864	CbGeAlD
Perhexiline—Shock—Sorafenib—thyroid cancer	0.00165	0.00824	CcSEcCtD
Perhexiline—Gait disturbance—Doxorubicin—thyroid cancer	0.00165	0.00822	CcSEcCtD
Perhexiline—Dizziness—Vandetanib—thyroid cancer	0.00165	0.00821	CcSEcCtD
Perhexiline—Hepatocellular injury—Doxorubicin—thyroid cancer	0.00161	0.00803	CcSEcCtD
Perhexiline—CPT1A—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.00161	0.00808	CbGpPWpGaD
Perhexiline—Anorexia—Sorafenib—thyroid cancer	0.0016	0.00798	CcSEcCtD
Perhexiline—Vomiting—Vandetanib—thyroid cancer	0.00158	0.00789	CcSEcCtD
Perhexiline—Rash—Vandetanib—thyroid cancer	0.00157	0.00783	CcSEcCtD
Perhexiline—Dermatitis—Vandetanib—thyroid cancer	0.00157	0.00782	CcSEcCtD
Perhexiline—Headache—Vandetanib—thyroid cancer	0.00156	0.00778	CcSEcCtD
Perhexiline—CYP2B6—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00152	0.00761	CbGpPWpGaD
Perhexiline—CPT1A—PPARA activates gene expression—PPARG—thyroid cancer	0.00151	0.00757	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—NDUFA13—thyroid cancer	0.0015	0.00755	CbGpPWpGaD
Perhexiline—Nausea—Vandetanib—thyroid cancer	0.00148	0.00737	CcSEcCtD
Perhexiline—CPT1A—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.00147	0.0074	CbGpPWpGaD
Perhexiline—CPT2—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.00147	0.00736	CbGpPWpGaD
Perhexiline—Decreased appetite—Sorafenib—thyroid cancer	0.00146	0.00728	CcSEcCtD
Perhexiline—Fatigue—Sorafenib—thyroid cancer	0.00145	0.00722	CcSEcCtD
Perhexiline—CPT2—Metabolism—CHST14—thyroid cancer	0.00141	0.0071	CbGpPWpGaD
Perhexiline—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00137	0.00685	CcSEcCtD
Perhexiline—CPT1A—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.00134	0.00673	CbGpPWpGaD
Perhexiline—CYP2B6—Metapathway biotransformation—CHST14—thyroid cancer	0.00134	0.00672	CbGpPWpGaD
Perhexiline—Urticaria—Sorafenib—thyroid cancer	0.00134	0.00665	CcSEcCtD
Perhexiline—Abdominal pain—Sorafenib—thyroid cancer	0.00133	0.00662	CcSEcCtD
Perhexiline—Hypoglycaemia—Epirubicin—thyroid cancer	0.0013	0.00645	CcSEcCtD
Perhexiline—Diplopia—Epirubicin—thyroid cancer	0.00126	0.0063	CcSEcCtD
Perhexiline—CPT1A—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.00124	0.00623	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—MINPP1—thyroid cancer	0.00123	0.00616	CbGpPWpGaD
Perhexiline—Asthenia—Sorafenib—thyroid cancer	0.00121	0.00601	CcSEcCtD
Perhexiline—Hypoglycaemia—Doxorubicin—thyroid cancer	0.0012	0.00597	CcSEcCtD
Perhexiline—Ataxia—Epirubicin—thyroid cancer	0.00119	0.00592	CcSEcCtD
Perhexiline—Diplopia—Doxorubicin—thyroid cancer	0.00117	0.00583	CcSEcCtD
Perhexiline—CPT2—Metabolism—HPGD—thyroid cancer	0.00114	0.00572	CbGpPWpGaD
Perhexiline—Muscular weakness—Epirubicin—thyroid cancer	0.00111	0.00555	CcSEcCtD
Perhexiline—Dizziness—Sorafenib—thyroid cancer	0.00111	0.00554	CcSEcCtD
Perhexiline—Ataxia—Doxorubicin—thyroid cancer	0.0011	0.00548	CcSEcCtD
Perhexiline—Vomiting—Sorafenib—thyroid cancer	0.00107	0.00532	CcSEcCtD
Perhexiline—Rash—Sorafenib—thyroid cancer	0.00106	0.00528	CcSEcCtD
Perhexiline—Dermatitis—Sorafenib—thyroid cancer	0.00106	0.00527	CcSEcCtD
Perhexiline—Headache—Sorafenib—thyroid cancer	0.00105	0.00525	CcSEcCtD
Perhexiline—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00105	0.00525	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—NDUFA13—thyroid cancer	0.00104	0.00523	CbGpPWpGaD
Perhexiline—Muscular weakness—Doxorubicin—thyroid cancer	0.00103	0.00514	CcSEcCtD
Perhexiline—CPT1A—AMPK Signaling—TP53—thyroid cancer	0.00102	0.00514	CbGpPWpGaD
Perhexiline—CPT1A—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.00102	0.0051	CbGpPWpGaD
Perhexiline—Nausea—Sorafenib—thyroid cancer	0.000998	0.00497	CcSEcCtD
Perhexiline—Weight decreased—Epirubicin—thyroid cancer	0.000988	0.00492	CcSEcCtD
Perhexiline—CPT1A—Metabolism—CHST14—thyroid cancer	0.00098	0.00492	CbGpPWpGaD
Perhexiline—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000955	0.00476	CcSEcCtD
Perhexiline—Sweating—Epirubicin—thyroid cancer	0.000934	0.00465	CcSEcCtD
Perhexiline—CPT1A—Circadian rythm related genes—PPARG—thyroid cancer	0.00093	0.00467	CbGpPWpGaD
Perhexiline—CYP2D6—Metapathway biotransformation—CHST14—thyroid cancer	0.00093	0.00467	CbGpPWpGaD
Perhexiline—CPT2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000925	0.00464	CbGpPWpGaD
Perhexiline—CYP2B6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000917	0.00461	CbGpPWpGaD
Perhexiline—Weight decreased—Doxorubicin—thyroid cancer	0.000914	0.00456	CcSEcCtD
Perhexiline—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000912	0.00458	CbGpPWpGaD
Perhexiline—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000883	0.0044	CcSEcCtD
Perhexiline—Hepatitis—Epirubicin—thyroid cancer	0.000874	0.00436	CcSEcCtD
Perhexiline—CPT1A—AMPK Signaling—AKT1—thyroid cancer	0.000865	0.00434	CbGpPWpGaD
Perhexiline—Sweating—Doxorubicin—thyroid cancer	0.000864	0.0043	CcSEcCtD
Perhexiline—Flushing—Epirubicin—thyroid cancer	0.000812	0.00404	CcSEcCtD
Perhexiline—Hepatitis—Doxorubicin—thyroid cancer	0.000809	0.00403	CcSEcCtD
Perhexiline—CPT1A—Metabolism—HPGD—thyroid cancer	0.00079	0.00397	CbGpPWpGaD
Perhexiline—Flushing—Doxorubicin—thyroid cancer	0.000751	0.00374	CcSEcCtD
Perhexiline—Tension—Epirubicin—thyroid cancer	0.000747	0.00372	CcSEcCtD
Perhexiline—CYP2B6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000743	0.00373	CbGpPWpGaD
Perhexiline—Nervousness—Epirubicin—thyroid cancer	0.000739	0.00368	CcSEcCtD
Perhexiline—Tension—Doxorubicin—thyroid cancer	0.000691	0.00344	CcSEcCtD
Perhexiline—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000689	0.00346	CbGpPWpGaD
Perhexiline—Nervousness—Doxorubicin—thyroid cancer	0.000684	0.00341	CcSEcCtD
Perhexiline—Syncope—Epirubicin—thyroid cancer	0.000683	0.0034	CcSEcCtD
Perhexiline—Loss of consciousness—Epirubicin—thyroid cancer	0.000669	0.00333	CcSEcCtD
Perhexiline—Convulsion—Epirubicin—thyroid cancer	0.00066	0.00329	CcSEcCtD
Perhexiline—CPT2—Metabolism—TPR—thyroid cancer	0.000655	0.00329	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—PRKAR1A—thyroid cancer	0.000644	0.00323	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000641	0.00322	CbGpPWpGaD
Perhexiline—CYP2B6—head—thyroid cancer	0.000639	0.0321	CbGeAlD
Perhexiline—CPT1A—Circadian rythm related genes—PTEN—thyroid cancer	0.000638	0.0032	CbGpPWpGaD
Perhexiline—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000637	0.0032	CbGpPWpGaD
Perhexiline—Syncope—Doxorubicin—thyroid cancer	0.000632	0.00315	CcSEcCtD
Perhexiline—Loss of consciousness—Doxorubicin—thyroid cancer	0.000619	0.00308	CcSEcCtD
Perhexiline—Shock—Epirubicin—thyroid cancer	0.000611	0.00304	CcSEcCtD
Perhexiline—Convulsion—Doxorubicin—thyroid cancer	0.00061	0.00304	CcSEcCtD
Perhexiline—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000608	0.00305	CbGpPWpGaD
Perhexiline—Hyperhidrosis—Epirubicin—thyroid cancer	0.000601	0.00299	CcSEcCtD
Perhexiline—Anorexia—Epirubicin—thyroid cancer	0.000592	0.00295	CcSEcCtD
Perhexiline—CPT2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000584	0.00293	CbGpPWpGaD
Perhexiline—Shock—Doxorubicin—thyroid cancer	0.000566	0.00282	CcSEcCtD
Perhexiline—Insomnia—Epirubicin—thyroid cancer	0.000562	0.0028	CcSEcCtD
Perhexiline—Paraesthesia—Epirubicin—thyroid cancer	0.000558	0.00278	CcSEcCtD
Perhexiline—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000556	0.00277	CcSEcCtD
Perhexiline—Anorexia—Doxorubicin—thyroid cancer	0.000548	0.00273	CcSEcCtD
Perhexiline—Decreased appetite—Epirubicin—thyroid cancer	0.00054	0.00269	CcSEcCtD
Perhexiline—Fatigue—Epirubicin—thyroid cancer	0.000536	0.00267	CcSEcCtD
Perhexiline—Insomnia—Doxorubicin—thyroid cancer	0.00052	0.00259	CcSEcCtD
Perhexiline—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000517	0.00259	CbGpPWpGaD
Perhexiline—Paraesthesia—Doxorubicin—thyroid cancer	0.000516	0.00257	CcSEcCtD
Perhexiline—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000508	0.00253	CcSEcCtD
Perhexiline—Decreased appetite—Doxorubicin—thyroid cancer	0.0005	0.00249	CcSEcCtD
Perhexiline—Fatigue—Doxorubicin—thyroid cancer	0.000496	0.00247	CcSEcCtD
Perhexiline—Urticaria—Epirubicin—thyroid cancer	0.000494	0.00246	CcSEcCtD
Perhexiline—Abdominal pain—Epirubicin—thyroid cancer	0.000491	0.00245	CcSEcCtD
Perhexiline—CPT2—Metabolism—SLC5A5—thyroid cancer	0.00049	0.00246	CbGpPWpGaD
Perhexiline—CYP2D6—head—thyroid cancer	0.000475	0.0239	CbGeAlD
Perhexiline—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00047	0.00234	CcSEcCtD
Perhexiline—CPT2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000459	0.00231	CbGpPWpGaD
Perhexiline—Urticaria—Doxorubicin—thyroid cancer	0.000457	0.00227	CcSEcCtD
Perhexiline—Abdominal pain—Doxorubicin—thyroid cancer	0.000454	0.00226	CcSEcCtD
Perhexiline—CPT1A—Metabolism—TPR—thyroid cancer	0.000454	0.00228	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—PRKAR1A—thyroid cancer	0.000446	0.00224	CbGpPWpGaD
Perhexiline—Asthenia—Epirubicin—thyroid cancer	0.000446	0.00222	CcSEcCtD
Perhexiline—CPT1A—Circadian rythm related genes—TP53—thyroid cancer	0.000436	0.00219	CbGpPWpGaD
Perhexiline—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000417	0.00209	CbGpPWpGaD
Perhexiline—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000414	0.00208	CbGpPWpGaD
Perhexiline—Asthenia—Doxorubicin—thyroid cancer	0.000412	0.00205	CcSEcCtD
Perhexiline—CPT2—Metabolism—RXRA—thyroid cancer	0.000412	0.00207	CbGpPWpGaD
Perhexiline—Dizziness—Epirubicin—thyroid cancer	0.000411	0.00205	CcSEcCtD
Perhexiline—CPT1A—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000405	0.00203	CbGpPWpGaD
Perhexiline—CPT2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.0004	0.00201	CbGpPWpGaD
Perhexiline—Vomiting—Epirubicin—thyroid cancer	0.000395	0.00197	CcSEcCtD
Perhexiline—CYP2B6—Biological oxidations—RXRA—thyroid cancer	0.000395	0.00198	CbGpPWpGaD
Perhexiline—Rash—Epirubicin—thyroid cancer	0.000392	0.00195	CcSEcCtD
Perhexiline—Dermatitis—Epirubicin—thyroid cancer	0.000391	0.00195	CcSEcCtD
Perhexiline—Headache—Epirubicin—thyroid cancer	0.000389	0.00194	CcSEcCtD
Perhexiline—Dizziness—Doxorubicin—thyroid cancer	0.00038	0.00189	CcSEcCtD
Perhexiline—Nausea—Epirubicin—thyroid cancer	0.000369	0.00184	CcSEcCtD
Perhexiline—Vomiting—Doxorubicin—thyroid cancer	0.000365	0.00182	CcSEcCtD
Perhexiline—Rash—Doxorubicin—thyroid cancer	0.000362	0.00181	CcSEcCtD
Perhexiline—Dermatitis—Doxorubicin—thyroid cancer	0.000362	0.0018	CcSEcCtD
Perhexiline—Headache—Doxorubicin—thyroid cancer	0.00036	0.00179	CcSEcCtD
Perhexiline—Nausea—Doxorubicin—thyroid cancer	0.000341	0.0017	CcSEcCtD
Perhexiline—CPT1A—Metabolism—SLC5A5—thyroid cancer	0.00034	0.00171	CbGpPWpGaD
Perhexiline—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000338	0.0017	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000318	0.0016	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—MINPP1—thyroid cancer	0.00029	0.00146	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—RXRA—thyroid cancer	0.000285	0.00143	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000278	0.00139	CbGpPWpGaD
Perhexiline—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000274	0.00138	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—PPARG—thyroid cancer	0.00026	0.00131	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—NDUFA13—thyroid cancer	0.000247	0.00124	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—CHST14—thyroid cancer	0.000232	0.00116	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—PTGS2—thyroid cancer	0.000205	0.00103	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—MINPP1—thyroid cancer	0.000202	0.00101	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—HPGD—thyroid cancer	0.000187	0.000939	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—PPARG—thyroid cancer	0.00018	0.000905	CbGpPWpGaD
Perhexiline—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000179	0.000901	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—PTEN—thyroid cancer	0.000178	0.000896	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—NDUFA13—thyroid cancer	0.000171	0.000861	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—CHST14—thyroid cancer	0.000161	0.00081	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—PTGS2—thyroid cancer	0.000142	0.000712	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—MINPP1—thyroid cancer	0.000132	0.000662	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—HPGD—thyroid cancer	0.00013	0.000653	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—PTEN—thyroid cancer	0.000124	0.000621	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—NDUFA13—thyroid cancer	0.000112	0.000563	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—TPR—thyroid cancer	0.000107	0.000539	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—PRKAR1A—thyroid cancer	0.000106	0.00053	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—CHST14—thyroid cancer	0.000105	0.000529	CbGpPWpGaD
Perhexiline—CPT2—Metabolism—AKT1—thyroid cancer	0.000103	0.000516	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—HPGD—thyroid cancer	8.5e-05	0.000427	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—SLC5A5—thyroid cancer	8.04e-05	0.000404	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—TPR—thyroid cancer	7.46e-05	0.000375	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	7.34e-05	0.000369	CbGpPWpGaD
Perhexiline—CPT1A—Metabolism—AKT1—thyroid cancer	7.12e-05	0.000358	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—RXRA—thyroid cancer	6.75e-05	0.000339	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—SLC5A5—thyroid cancer	5.59e-05	0.000281	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—TPR—thyroid cancer	4.88e-05	0.000245	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	4.8e-05	0.000241	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—RXRA—thyroid cancer	4.69e-05	0.000236	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—PPARG—thyroid cancer	4.26e-05	0.000214	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—SLC5A5—thyroid cancer	3.65e-05	0.000183	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—PTGS2—thyroid cancer	3.35e-05	0.000168	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—RXRA—thyroid cancer	3.07e-05	0.000154	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—PPARG—thyroid cancer	2.96e-05	0.000149	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—PTEN—thyroid cancer	2.93e-05	0.000147	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—PTGS2—thyroid cancer	2.33e-05	0.000117	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—PTEN—thyroid cancer	2.03e-05	0.000102	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—PPARG—thyroid cancer	1.94e-05	9.73e-05	CbGpPWpGaD
Perhexiline—CYP2B6—Metabolism—AKT1—thyroid cancer	1.69e-05	8.47e-05	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.52e-05	7.65e-05	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—PTEN—thyroid cancer	1.33e-05	6.68e-05	CbGpPWpGaD
Perhexiline—CYP2D6—Metabolism—AKT1—thyroid cancer	1.17e-05	5.88e-05	CbGpPWpGaD
Perhexiline—CYP3A4—Metabolism—AKT1—thyroid cancer	7.66e-06	3.85e-05	CbGpPWpGaD
